These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38101278)

  • 21. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
    Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
    J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.
    Llanos JP; Bell CF; Packnett E; Thiel E; Irwin DE; Hahn B; Ortega H
    J Asthma Allergy; 2019; 12():43-58. PubMed ID: 30774390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
    Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.
    Albers FC; Hozawa S; Bratton DJ; Yancey SW; Prazma CM; Humbert M; Liu MC
    Allergy; 2020 Apr; 75(4):942-946. PubMed ID: 31520471
    [No Abstract]   [Full Text] [Related]  

  • 32. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 33. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
    Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
    Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].
    Ito A; Miyoshi S; Toyota H; Suzuki Y; Uehara Y; Hattori S; Takeshita Y; Sakasegawa H; Kuramochi M; Kobayashi K; Sugimoto N; Nagase H
    Arerugi; 2022; 71(3):210-220. PubMed ID: 35569943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
    Akenroye AT; Heyward J; Keet C; Alexander GC
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.
    Akenroye A; Nopsopon T; Cho L; Moll M; Weiss ST
    Respir Res; 2023 Dec; 24(1):305. PubMed ID: 38057814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
    Dedaj R; Unsel L
    J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.